Stock A340570 T&L CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials T&L Co., Ltd.

Equities

A340570

KR7340570001

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
69,800 KRW -2.92% Intraday chart for T&L Co., Ltd. -0.57% +74.50%
2023 Tranche Update on T&L Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022. CI
2023 Tranche Update on T&L Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,73,939 3,84,454 2,92,207 3,22,880 5,61,812 - -
Enterprise Value (EV) 2 173.9 347.6 258.6 295 479.2 451.3 412.9
P/E ratio - 14.2 x 13.9 x 11.8 x 13.3 x 12.4 x 11.1 x
Yield - 0.85% 1.24% 1.38% 0.79% 1.25% 1.58%
Capitalization / Revenue 4.28 x 5.35 x 3.58 x 2.8 x 3.41 x 3.03 x 2.26 x
EV / Revenue 4.28 x 4.83 x 3.17 x 2.56 x 2.91 x 2.43 x 1.66 x
EV / EBITDA - 14.5 x 9.79 x 8.77 x 9.34 x 8.15 x 6.56 x
EV / FCF - 103 x -440 x 15.4 x 12.3 x 14.6 x -
FCF Yield - 0.97% -0.23% 6.49% 8.14% 6.87% -
Price to Book - 4.27 x 2.77 x 2.49 x 3.37 x 2.8 x 2.33 x
Nbr of stocks (in thousands) 8,128 8,128 8,072 8,072 8,072 - -
Reference price 3 21,400 47,300 36,200 40,000 69,800 69,800 69,800
Announcement Date 02/02/21 09/02/22 14/03/23 02/02/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 40.63 71.9 81.58 115.5 164.6 185.7 248.7
EBITDA 1 - 24.02 26.41 33.64 51.3 55.4 62.9
EBIT 1 9.592 22.33 24.31 30.84 50.65 57.6 81.45
Operating Margin 23.61% 31.06% 29.8% 26.71% 30.78% 31.02% 32.75%
Earnings before Tax (EBT) 1 - 23.43 25.56 33.06 51.2 54.95 61.9
Net income 1 - 19.45 21.12 27.44 44.9 50.53 69.7
Net margin - 27.06% 25.89% 23.76% 27.29% 27.22% 28.03%
EPS 2 - 3,334 2,602 3,399 5,234 5,614 6,316
Free Cash Flow 3 - 3,372 -587.5 19,139 39,000 31,000 -
FCF margin - 4,690.55% -720.18% 16,576.38% 23,701% 16,696.59% -
FCF Conversion (EBITDA) - 14,040.98% - 56,900.68% 76,023.39% 55,956.68% -
FCF Conversion (Net income) - 17,335.11% - 69,753.03% 86,859.69% 61,345.65% -
Dividend per Share 2 - 400.0 450.0 550.0 550.0 875.0 1,100
Announcement Date 02/02/21 09/02/22 14/03/23 02/02/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 22.32 14.79 23.62 20.46 22.71 27.04 36.45 30.03 21.94 24.81 51.5 40.5 43
EBITDA - - - - - - - - - - - - -
EBIT 1 5.609 4.672 8.253 6.109 5.276 8.852 12.57 8.435 0.9842 7.224 17.9 13.5 10
Operating Margin 25.13% 31.58% 34.94% 29.85% 23.24% 32.74% 34.48% 28.09% 4.49% 29.11% 34.76% 33.33% 23.26%
Earnings before Tax (EBT) 1 5.744 5.021 9.038 6.85 4.651 9.509 12.96 9.608 0.98 8.554 12.7 12.4 6.4
Net income 1 4.755 4.197 7.555 5.497 4.28 7.859 10.04 7.65 1.893 7.099 10.6 10.3 5.3
Net margin 21.3% 28.38% 31.99% 26.86% 18.85% 29.06% 27.53% 25.48% 8.63% 28.61% 20.58% 25.43% 12.33%
EPS - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 09/02/22 13/05/22 26/07/22 11/11/22 14/03/23 15/05/23 11/08/23 14/11/23 02/02/24 16/05/24 - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 36.8 33.6 27.8 82.6 111 149
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 2 - 3,372 -588 19,139 39,000 31,000 -
ROE (net income / shareholders' equity) - 24% 21.5% 23.3% 30% 26.8% 27.9%
ROA (Net income/ Total Assets) - 21.9% 19.6% 21.2% 26% 23% 21.5%
Assets 1 - 88.88 107.7 129.6 172.7 219.7 324.2
Book Value Per Share 3 - 11,084 13,050 16,050 20,729 24,900 30,003
Cash Flow per Share 3 - 2,338 1,896 4,038 4,841 6,052 6,749
Capex 1 - 15.6 16 13.5 9.25 10.5 6
Capex / Sales - 21.74% 19.61% 11.65% 5.62% 5.66% 2.41%
Announcement Date 02/02/21 09/02/22 14/03/23 02/02/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for T&L Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
69,800 KRW
Average target price
85,500 KRW
Spread / Average Target
+22.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
T&L CO., LTD. Stock T&L Co., Ltd.
+74.50% 405M
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.84% 182B
MEDTRONIC PLC Stock Medtronic plc
-4.20% 103B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.94B
CENCORA, INC. Stock Cencora, Inc.
+11.37% 46.73B
DEXCOM, INC. Stock DexCom, Inc.
-8.92% 45.14B
HOYA CORPORATION Stock Hoya Corporation
+5.82% 41.57B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+16.86% 30.48B
TERUMO CORPORATION Stock Terumo Corporation
+14.00% 24.26B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-6.98% 23.58B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. A340570 Stock
  4. Financials T&L Co., Ltd.